

Claims

1. A CD25 binding molecule which comprises at least one antigen binding site comprising at least one domain which comprises in sequence, the hypervariable regions CDR1, CDR2 and CDR3; said CDR1 having the amino acid sequence Arg-Tyr-Trp-Met-His, said CDR2 having the amino acid sequence Ala-Ile-Tyr-Pro-Gly-Asn-Ser-Asp-Thr-Ser-Tyr-Asn-Gln-Lys-Phe-Glu-Gly, and said CDR3 having the amino acid sequence Asp-Tyr-Gly-Tyr-Tyr-Phe-Asp-Phe; or direct equivalents thereof for use in the treatment of rheumatoid arthritis or inflammatory or hyperproliferative skin diseases.
2. A CD25 binding molecule according to claim 1 for use in the manufacturing of a medicament for use in the treatment of rheumatoid arthritis or inflammatory or hyperproliferative skin diseases in a patient in need of such treatment comprising administering to the patient an effective amount of a CD25 binding molecule according to claim 1.
3. A pharmaceutical composition for the treatment of rheumatoid arthritis or inflammatory or hyperproliferative skin diseases comprising a CD25 binding molecule according to claim 1 and a pharmaceutically acceptable carrier or diluent.
4. A method for the treatment of rheumatoid arthritis or inflammatory or hyperproliferative skin diseases in a patient in need of such treatment comprising administering to the patient an effective amount of a CD25 binding molecule according to claim 1.
5. A method for the treatment of rheumatoid arthritis or inflammatory or hyperproliferative skin diseases in a subject in need of such treatment comprising administering to said subject an effective amount of a) a CD25 binding molecule according to claim 1 and b) a further drug substance being effective in the treatment of rheumatoid arthritis or inflammatory or hyperproliferative skin diseases.
6. A method for the treatment of inflammatory or hyperproliferative skin diseases in a subject in need of such treatment comprising administering an effective amount of a CD25 binding molecule according to claim 1 and applying a non-drug inflammatory or hyperproliferative skin disease therapy, e.g. UV light therapy, to said subject.

7. A therapeutic combination for use in any of the methods as described in (i) to (iv) said combination including a pharmaceutical composition comprising a CD25 binding molecule according to claim 1, and further including at least one pharmaceutical composition comprising a further drug substance effective in the treatment of rheumatoid arthritis or inflammatory or hyperproliferative skin diseases.

8. A method according to any one of claims 4 to 6, wherein the CD25 binding molecule is basiliximab.

9. A CD25 binding molecule according to claim 1 or 2, which is basiliximab.

10. A composition or combination according to claim 3 or 7, wherein the CD25 binding molecule is basiliximab.

FOIA b 7 - DATED 09/27/2007